Breaking News

Abbott’s RealTime SARS-CoV-2 Test Receives EUA

System uses polymerase chain reaction (PCR) technology and has the ability to run high volumes of up to 470 tests in 24 hours

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Abbott received Emergency Use Authorization (EUA) from the U.S. FDA for the company’s molecular test for novel coronavirus (COVID-19). Abbott is immediately shipping 150,000 Abbott RealTime SARS-CoV-2 EUA tests to existing customers in the U.S. The tests are used on the company’s m2000 RealTime System. Abbott will be working with health systems and government authorities to deploy additional m2000 systems as needed. The Abbott m2000 RealTime System uses polymerase chain reaction (...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters